Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02655887 · ClinicalTrials.gov registry record · NA
BARD® The VENOVO™ Venous Stent Study for Treatment of Iliofemoral Occlusive Disease
A NA study of Peripheral Vascular Disease and Venous Disease, sponsored by C. R. Bard.
- Completed
- Registry status
- NA
- Development phase
- 170
- Enrollment target
- 20
- Study locations
NCT02655887 is a NA study of Peripheral Vascular Disease and Venous Disease that has completed, run by C. R. Bard. The registered enrollment target is 170 participants, below the 276-participant average among 25 other Peripheral Vascular Disease trials with a reported enrollment target (38% lower). The trial reports 20 study locations across 13 states.
The verdict
NCT02655887, a NA study of Peripheral Vascular Disease and Venous Disease, has completed, sponsored by C. R. Bard.
- COMPLETED
- Registry status
- NA
- Development phase
- 170 participants
- Enrollment target
- 20
- Study locations
Study Summary
The BARD® Venovo™ Venous Stent Study is a non-randomized clinical study intended to collect confirmatory evidence of the safety and effectiveness of the Venous Stent for the treatment of iliofemoral occlusive disease.
Conditions Studied
Interventions
- DEVICE VENOVO™ Venous Stent
Study Locations (20)
Other
- Uniklinik RWTH - Aachen
- Klinikum Arnberg - Arnsberg
- Universitaets-Herrzentrum Freiburg-Bad Krozingen - Bad Krozingen
- University Hospital Galway - Galway
- MUMC Maastricht - Maastricht
- Fundacion de investigacion HM Hospitales - Madrid
Connecticut
- Vascular Breakthroughs, LLC - Darien
- Yale University - New Haven
Virginia
- Centra Health, Inc., dba Stroobants Cardiovascular Center - Lynchburg
- Sentara Medical Group - Virginia Beach
Iowa
- Midwest Cardiovascular Research Foundation - Davenport
Michigan
- Metro Health Hospital - Wyoming
Missouri
- Cox Medical Centers - Springfield
New York
- Mount Sinai Medical Center - New York
North Carolina
- North Carolina Heart and Vascular - Raleigh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 170 participants |
| Start Date | 2016-06-15 |
| Est. Completion | 2020-10-30 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02655887
The ClinicalTrials.gov registry entry for NCT02655887 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 170 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 276-participant average among 25 other Peripheral Vascular Disease trials with a reported enrollment target (38% lower). The listed sponsor is C. R. Bard, which has 75 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Peripheral Vascular Disease appearing as the primary indexed condition, and to 1 intervention - of which VENOVO™ Venous Stent is the first listed.
NCT02655887 reports 20 study locations spanning 13 distinct geographic areas - top geographies include Other, Connecticut, Virginia.
Frequently Asked Questions
What is clinical trial NCT02655887 about?
NCT02655887 is a clinical study titled "BARD® The VENOVO™ Venous Stent Study for Treatment of Iliofemoral Occlusive Disease". The BARD® Venovo™ Venous Stent Study is a non-randomized clinical study intended to collect confirmatory evidence of the safety and effectiveness of the Venous Stent for the treatment of iliofemoral occlusive disease.
What is the current status of trial NCT02655887?
This trial is currently completed. It is a NA study. The enrollment target is 170 participants. The study started on 2016-06-15. Estimated completion is 2020-10-30.
What conditions does trial NCT02655887 study?
This clinical trial studies the following conditions: Peripheral Vascular Disease, Venous Disease, May-Thurner Syndrome, Iliofemoral Occlusive Disease.
What interventions are being tested in trial NCT02655887?
The interventions under investigation include: VENOVO™ Venous Stent (DEVICE).
Who is sponsoring clinical trial NCT02655887?
This trial is sponsored by C. R. Bard, which has 75 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02655887 being conducted?
This trial has 20 study locations across Connecticut, Iowa, Michigan, Missouri, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Peripheral Vascular Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Far Red Light to Improve Functioning in PAD
RECRUITING · NA
-
Leg Exercise Assistive Paddling (LEAP) Therapy for Peripheral Artery Disease
RECRUITING · NA
-
ENhancing Exercise with LIGHT to Improve Functioning in PAD
RECRUITING · NA
-
The OPC for Optimal Delivery of Paclitaxel for the Prevention of Endovascular Restenosis - Above and Below the Knee
COMPLETED · NA
-
A Multi-center Clinical Trial of the Misago™ Self-Expanding Stent System for Superficial Femoral Artery
COMPLETED · NA
-
JetStream (JS) Atherectomy in Femoropopliteal In-Stent Restenotic Lesions
COMPLETED · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.